Semaglutide
Ozempic / Wegovy analog
Mechanism of Action
GLP-1 receptor agonist. Activates incretin signaling, slows gastric emptying, suppresses appetite via hypothalamic pathways, and enhances glucose-dependent insulin secretion.
Key Benefits
- Significant sustained weight loss (avg ~15% body weight in trials)
- Improved glycemic control and insulin sensitivity
- Reduced cardiovascular event risk (SUSTAIN/STEP trials)
- Appetite suppression and reduced food cravings
Dosing Protocol
Titrate slowly over 16–20 weeks; maintain at the lowest effective dose. Weight regain common on discontinuation.
Ideal Candidates
Adults with BMI ≥30, or ≥27 with comorbidity. Studied for metabolic syndrome.
Side Effects & Safety
Nausea (esp. on titration), vomiting, diarrhea, constipation, rare pancreatitis risk.
Regulatory Status
Gray AreaFDA shortage compounding authority is closing — monitor the shortage list and pharmacy counsel.
Frequently asked
What is Semaglutide?+
Semaglutide (Ozempic / Wegovy analog) is a peptide studied for fat loss and appetite control. GLP-1 receptor agonist. Activates incretin signaling, slows gastric emptying, suppresses appetite via hypothalamic pathways, and enhances glucose-dependent insulin secretion.
What is the dosing protocol for Semaglutide?+
Literature commonly references 0.25 mg/wk (low) to 1.0 mg/wk (maintenance) via SubQ weekly, on a ongoing cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of Semaglutide?+
FDA shortage compounding authority is closing — monitor the shortage list and pharmacy counsel.
Where can I access Semaglutide?+
Research-grade Semaglutide is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.
More in Weight Management
Used in these stacks
Semaglutide appears in 1 research protocol in the Stackhaus Academy library.